ArticleFrontiers in pharmacology2025
Trends in good laboratory practice studies submitted for the marketing authorization of pharmaceuticals in Japan.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmaceuticals and Medical Devices Agencies (PMDA) receives the non-clinical safety studies following Good Laboratory Practice (GLP) for the marketing authorization of medical products. Here we analyzed the trends of GLP-compliant non-clinical studies (GLP studies) submitted to PMDA from FY2017 to FY2023. Geographical analysis of the origin of studies revealed that the share of Japanese studies slightly decreased over years, reflecting the drug lag/loss in Japan. This was supported by the analysis of the time from the completion of GLP studies to submissions. Importantly, studies from China and Taiwan were emerging, reflecting the active drug development in China, which is not the adherent to the OECD Mutual Acceptance of Data (MAD). We also discuss the PMDA's policies on the GLP studies conducted in non-MAD countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.